Health Cures

Nutriment – Minerals -2/3

### MAGNESIUM:

## Magnesium deficiency may contribute to osteoporosis rise, http://www.nutraingredients.com/news/news-ng.asp?n=57511-magnesium-deficiency-may

21/01/2005 – Prolonged magnesium deficiency leads to osteoporosis in rats, finds new research, which could present a warning to many populations not getting adequate levels of the mineral through their diets.

The scientists from Tel-Aviv University and the University of Luebeck in Germany compared rats fed a magnesium-deficient diet daily with rats fed a diet with adequate levels of the mineral over a period of one year.

The mean bone density of the vertebral bone and the femoral region bone was significantly higher in the control group than in the magnesium deficient group B. The researchers also found indicators of osteoporosis, according to the report in the December issue of the Journal of the American College of Nutrition (vol 23, no 6, 704S-711S).

While the findings cannot yet be extrapolated to prevention of the disease in humans, they suggest that further research should be done in the wake of a steady rise in osteoporosis. It currently affects 30 million people (predominantly women) worldwide and the number of related hip fractures is estimated to increase 135 per cent in the EU from 414,000 to 972,000 by the year 2050.

Researchers have also recently identified a deficiency of the mineral in European populations.

Writing in a special supplement on magnesium in the same journal, Dr Jean Durlach from the International Society for the Development of Research on Magnesium at the Pierre et Marie Curie University in Paris says that about 20 per cent of the French population consumes less than two-thirds of the RDA for magnesium, with women in particular having low intakes.

Mineral suppliers have started to see increasing demand for magnesium.
“Demand for magnesium is going up and will in the end become a product like calcium. There is awareness that it is just as important,” Ernst Guenther, product manager at Boehringer’s fine chemicals division, recently told NutraIngredients.com.

Guenther added that recent advertising campaigns for magnesium supplements in Germany have also played a role in driving demand for the mineral in the food industry.

However the bone health category, worth £60 million in the UK in 2002, remains significantly smaller than others like gut health, at an estimated value of £111.2 million at the same time.

And a recent check on new products fortified with the mineral shows that few are communicating the benefits to bone health.

## Magnesium Bicarbonate Water, Russell J. Beckett,From : http://www.rexresearch.com

The Star ( 9 Apr 2002):”Water that Adds Years to Cattle Life and Cures Ailments

A Sydney soft drinks producer has been inundated with demand for his latest product, a mineral-rich water which doubles the life of cattle and is claimed to cure ailments like arthritis and osteoporosis. Developed by former vet Russell Beckett, who has a doctorate in biochemical pathology, “Unique Water” has just gone on sale after testing by 100 Australians. One is Paul Sheehan, a respected Sydney journalist, who said in the Sydney Morning Herald at the weekend how it has cured him of a series of long-term autoimmune diseases. A letter from Sheehan’s doctor said: “He has anklyosing spondylitis, and is now undergoing investigation for lupus erythematosis. He suffers constant back and neck pains, florid facial rash, extreme fatigue and shoulder pains.”

The illness is incurable and requires constant treatment. But Sheehan said after taking Beckett’s water for two years, he was no longer consuming drugs of any kind, suffered no back or neck pain nor any of the other symptoms of the diseases. “For someone with a cocktail of chronic conditions, I feel suspiciously normal and relatively pain-free,” he said. A number of prominent people are said to have undergone similar cures since starting to drink what they call “magic water”, which is richer in some minerals and found naturally in some places. None has a financial interest in the product.

Beckett, who has spent 20 years researching it, has been granted patents in Australia and in the United States where the Patent and Trademark Office describes it as “A method of preventing or treating inflammatory diseases or degenerative diseases in a mammal.” His claimed breakthrough is based on the proposition that acids formed from carbon dioxide produced by the body contribute to fatigue and degeneration and are the building blocks for all inflammatory diseases. They are key factors in rheumatoid and osteo-athritis, osteoporosis and some cancers and skin diseases.

Beckett’s key breakthrough is claimed to be the anti-acid magnesium bicarbonate in the water which travels down the individual cells where it acts as a protective buffer against excess carbon dioxide and acid. He tried to prove his theories by testing the ingredients on sheep for many years before realizing that such water must occur naturally somewhere. He found it, by coincidence, in the Monaro region of the Snowy Mountains near Canberrawhere farmers had known for years about the longevity of cattle and sheep. The government-run Commonwealth Scientific and Industrial Research Organisation had been researching for 35 years why some animals lived twice as long, and most lived at least 30% longer.

Despite the success of the trials in Sydney, Beckett acknowledges his theory will take many years and many thousands more people to prove. But through a Sydney soft drinks manufacturer Bert’s Soft Drinks, Beckett has organized commercial sales of the water. “We have been absolutely inundated with calls for it since it went on sale on Saturday,” said Bert’s managing director Arthur Shelly. “It has gone from nowhere to our top selling product overnight.” AFP

## US Patent # 6,328,997 Russell J. Beckett:

Aqueous Metal Bicarbonate Solution and Method of Use

Abstract: An aqueous neutral to mildly alkaline metal bicarbonate solution is disclosed. The solution comprises metal bicarbonate dissolved in the solution, the metal bicarbonate comprising bicarbonate anions and metal cations. In addition there is a pH adjusting agent in the solution in an amount whereby the solution is at a neutral to mildly alkaline pH. Also disclosed is a process of preparing an aqueous neutral to mildly alkaline metal bicarbonate solution comprising bicarbonate anions and metal cations. The process comprises reacting a compound selected from the group consisting of metal carbonate, metal carbonate hydroxide, metal oxide, metal hydroxide and any mixture thereof with an effective concentration of a pH adjusting agent to produce the aqueous neutral to mildly alkaline metal bicarbonate solution, wherein the pH adjusting agent is present in an amount whereby the solution is at a neutral to mildly alkaline pH.

Further disclosed are a method of preventing and/or treating certain inflammatory diseases and/or degenerative diseases in a mammal, a method of preventing and/or treating certain viral diseases in a mammal, a method of decreasing and/or treating senescence and/or of increasing longevity in a mammal, a method of scavenging protons in a mammal, a method of decreasing proton concentrations in a mammal by altering carbonic anhydrase enzyme reactions in said mammal, a method of decreasing inflammation and/or inflammatory conditions in a mammal and a method of increasing motor activity and/or decreasing fatigue in a mammal.

# Parent Case Text

– CROSS-REFERENCE TO RELATED APPLICATIONS

This is a continuation of Application No. 09/041,787 filed on Mar. 13, 1998 now U.S. Pat. No. 6,048,553.

– Claims:

What is claimed is:
1. A method of decreasing or treating senescence or of increasing longevity in a mammal comprising administering to said mammal an effective amount of an aqueous neutral to mildly alkaline metal bicarbonate solution comprising metal bicarbonate dissolved in the solution, said metal bicarbonate comprising bicarbonate anions and metal cations, and a pH adjusting agent in the solution in an amount whereby the solution is at a neutral to mildly alkaline pH and said metal cation is substantially magnesium.

2. A method of decreasing inflammation or inflammatory conditions in a mammal comprising administering to said mammal an effective amount of an aqueous neutral to mildly alkaline metal bicarbonate solution comprising metal bicarbonate dissolved in the solution, said metal bicarbonate comprising bicarbonate anions and metal cations, and a pH adjusting agent in the solution in an amount whereby the solution is at a neutral to mildly alkaline pH and said metal cation is substantially magnesium.

3. A method of increasing motor activity or decreasing fatigue in a mammal comprising administering to said mammal an effective amount of an aqueous neutral to mildly alkaline metal bicarbonate solution comprising metal bicarbonate dissolved in the solution, said metal bicarbonate comprising bicarbonate anions and metal cations, and a pH adjusting agent in the solution in an amount whereby the solution is at a neutral to mildly alkaline pH and said metal cation is substantially magnesium.

4. The method of any one of claims 1, 2 or 3, wherein said mammal is human and said aqueous neural to mildly alkaline metal bicarbonate solution is administered to said human on an empty stomach.

5. A method of preventing or treating inflammatory diseases or degenerative diseases in a mammal in need of such prevention or treatment comprising administering to said mammal an effective amount of an aqueous neutral to mildly alkaline metal bicarbonate solution, said solution comprising magnesium bicarbonate wherein the bicarbonate anions are in a concentration of 600 mg per litre of the solution and the magnesium cation is in a concentration of 120 mg per litre of the solution and sodium bicarbonate wherein the bicarbonate anions are in a concentration of 350 mg per litre of the solution, the solution having a pH of 8.0 to 8.6 and a temperature in the range 0 to 20.degree. C.

# Description:

– TECHNICAL FIELD

This invention relates to an aqueous metal bicarbonate solution, a process of preparing the aqueous metal bicarbonate solution and a method of preventing and treating certain inflammatory diseases, degenerative diseases and viral diseases in mammals. Generally the certain inflammatory diseases, degenerative diseases and viral diseases in mammals are those that require extracellular or intracellular acidic conditions or extracellular or intracellular proton concentrations at some point in disease process or disease pathogenesis.

Typically the certain inflammatory diseases, degenerative diseases and viral diseases in mammals are those that require the activities of carbonic anhydrase enzymes and/or the activities of acid (aspartic) protease enzymes and/or the activities of endosomal or lysosomal acid-requiring-enzymes and/or the activities of V-type ATPase proton pumps at some point in disease process or disease pathogenesis. Typically the certain inflammatory diseases, degenerative diseases and viral diseases in mammals are represented by the diseases of arthritis and influenza.

This invention relates to a method of using an aqueous metal bicarbonate solution to decrease senescence and to increase longevity in mammals. Generally senescence is decreased and longevity is increased in mammals by improving the buffering capacity of the extracellular and intracellular fluids of the body. Generally senescence is decreased and longevity is increased in mammals by the improved buffering capacity causing a decrease in proton concentrations in the extracellular and intracellular fluids of the body. Typically senescence is decreased and longevity is increased in mammals by improving the buffering capacity of the extracellular and intracellular bicarbonate buffers. Typically senescence is decreased and longevity is increased in mammals by the improved extracellular and intracellular bicarbonate buffers causing a decrease in proton concentrations.

– BACKGROUND ART

Certain inflammatory diseases, degenerative diseases and viral diseases are major causes of morbidity and mortality in mammals. Typically these diseases are represented by the diseases of arthritis and influenza.

Arthritis is any inflammatory condition of the joints, characterised by pain and swelling. Osteoarthritis is the most common form of arthritis in which one or many joints undergo degenerative changes. Treatment includes rest of the involved joints, heat, and antiinflammatory drugs. Intraarticular injections of corticosteroids may give relief. Surgical treatment is sometimes necessary and may reduce pain and greatly improve the function of the joint. However these treatments, apart from surgical treatment, only provide temporary relief and some may have severe side reactions.

Influenza is a highly contagious infection of the respiratory tract caused by a myxovirus and transmitted by airborne droplet infection. It occurs in isolated cases, epidemics and pandemics. Treatment is symptomatic and usually involves bed rest, antipyretics such as aspirin and drinking of fluids. New strains of the virus emerge at regular intervals so it is difficult to take preventative measures to avoid the infection. There is a need for a method to prevent and to treat certain inflammatory diseases, degenerative diseases and viral diseases in mammals. There is a need for a method to prevent and to treat arthritis and influenza in mammals.

Senescence in mammals is characterised by progressive oxidations of the structural and functional molecules that constitute body cells and tissues. Oxidations of the structural and functional molecules in body cells and tissues are increased in rate by acidic conditions. Oxidations of structural and functional molecules are increased in rate by the presence of excess proton concentrations. There is a need for a method to prevent and treat excess proton concentrations in body cells so that oxidations of structural and functional molecules are decreased in rate. There is a need for a method to decrease and treat senescence in mammals.

– OBJECTS OF INVENTION

It is an object of this invention to provide an aqueous metal bicarbonate solution to prevent and to treat certain inflammatory diseases, degenerative diseases and viral diseases in mammals. It is a further object of this invention to provide a process of preparing the aqueous metal bicarbonate solution. It is also an object of this invention to provide methods for the prevention and treatment of certain inflammatory diseases, degenerative diseases and viral diseases in mammals using the aqueous metal bicarbonate solution.

Generally the certain inflammatory diseases, degenerative diseases and viral diseases in mammals are those that require extracellular or intracellular acidic conditions or extracellular or intracellular proton concentrations at some point in disease process or disease pathogenesis. Typically the certain inflammatory diseases, degenerative diseases and viral diseases in mammals are those that require the activities of carbonic anhydrase enzymes and/or the activities of acid (aspartic) protease enzymes and/or the activities of endosomal or lysosomal acid-requiring-enzymes and/or the activities of V-type ATPase proton pumps at some point in disease process or disease pathogenesis. Typically the certain inflammatory diseases, degenerative diseases and viral diseases in mammals are represented by the diseases of arthritis and influenza.

It is an object of this invention to provide an aqueous metal bicarbonate solution to decrease senescence and to treat senescence and to increase longevity in mammals. It is a further object of this invention to provide a process of preparing the aqueous metal bicarbonate solution. It is also an object of this invention to provide methods for the decrease of senescence and the treatment of senescence and the increase in longevity in mammals using the aqueous metal bicarbonate solution. Generally senescence is decreased and longevity is increased in mammals by improving the buffering capacity of the extracellular and intracellular fluids of the body. Generally senescence is decreased and longevity is increased in mammals by the improved buffering capacity causing a decrease in proton concentrations in the extracellular and intracellular fluids of the body.

Typically senescence is decreased and longevity is increased in mammals by improving the buffering capacity of the extracellular and intracellular bicarbonate buffers. Typically senescence is decreased and longevity is increased in mammals by the improved extracellular and intracellular bicarbonate buffers causing a decrease in proton concentrations.

– DISCLOSURE OF INVENTION

According to a first embodiment of the present invention there is provided an aqueous metal bicarbonate solution comprising a stoichiometric concentration of bicarbonate anions and a corresponding substantially stoichiometric concentration of metal cations in association with the bicarbonate anions, the metal bicarbonate being present in a therapeutically effective amount and an acceptable carbon dioxide-containing-aqueous diluent to maintain the metal bicarbonate in the aqueous diluent.

etc…

– BRIEF DESCRIPTION OF DRAWINGS

FIG. 2 is a photograph showing osteoarthritis in the joints of the fingers and thumb. Osteoarthritis before the consumption of aqueous metal bicarbonate solution. Note the swelling and `claw-like` hand resulting from joint flexion and joint displacement. (The patient was pushing down with her hand `as hard as possible` in an attempt to place her hand flat on the underlying surface.); and

FIG. 3 is a photograph showing osteoarthritis in the joints of the fingers and thumb. Osteoarthritis twelve months after commencement of the consumption of aqueous metal bicarbonate solution. Note that the fingers can be extended and the joints are `straighter` than twelve months previously. (The patient had placed her hand flat on the underlying surface without exerting any force.)

– BEST MODE AND OTHER MODE(S) FOR CARRYING OUT THE INVENTION

Magnesium bicarbonate is a natural hydrated salt which exists only in an aqueous solution. It may be formed in spring water by an ion exchange process between the protons in carbonic acid (formed from the hydration of carbon dioxide located in the atmosphere, organic material, soils and rocks) and the magnesium in the constituent minerals of rocks (particularly the ferromagnesian minerals known as pyroxene and olivine that constitute basalt rocks).

etc…

– EXAMPLE 2

An Experiment to Demonstrate Bicarbonate Anion Translocation from Aqueous Metal Bicarbonate Solution into the Mammalian Body Against a Bicarbonate Anion Concentration Gradient.

Mammalian plasma contains bicarbonate anions at a concentration about 25 mmol (HCO3sup.- 1,500 mg per litre). When ingested, aqueous metal bicarbonate solution produces biochemical, physiological and medical effects at bicarbonate anion concentrations about 16 mmol (HCO3sup.- 950 mg per litre). Aqueous metal bicarbonate solution, at bicarbonate anion concentration about 16 mmol, contains two thirds the bicarbonate anion concentration of plasma, so bicarbonate anions must be translocated into the mammalian body against a bicarbonate anion concentration gradient.

Mammalian plasma contains cations at concentrations around Mg.sup.2+ 24 mg per litre, Na.sup.+ 3,300 mg per litre, K.sup.+ 175 mg per litre and Ca.sup.2+ 100 mg per litre. Aqueous metal bicarbonate solution commonly contains cations at concentrations around Mg.sup.2+ 120 mg per litre, Na.sup.+ 135 mg per litre, K.sup.+ 100 mg per litre and Ca.sup.2+ 20 mg per litre. Aqueous metal bicarbonate solution commonly contains 5 times the magnesium cation concentration of plasma. Other cations are present commonly in aqueous metal bicarbonate solution in concentrations lower than plasma.

The concentrations of cations and anions in plasma can be compared with concentrations of cations and anions in aqueous metal bicarbonate solution by examination of the following table:

Concentrations of cations and anions
Aqueous metal
Ion………………………………….. Plasma ……………….. bicarbonate solution
Cl.sup.-…………………………3,600 mg/litre……………………….0 mg/litre
Na.sup.+ ……………………….. 3,300 mg/litre …………………… 135 mg/litre
HCO.sub.3.sup.- …………….. 1,500 mg/litre ……………………950 mg/litre
K.sup.+ ……………………………. 175 mg/litre ………………………100 mg/litre
Ca.sup.2+ …………………………100 mg/litre ……………………… 20 mg/litre
Mg.sup.2+ ………………………… 24 mg/litre ……………………….. 120 mg/litre

It is suggested that sodium cations and chloride anions leave plasma along their respective concentration gradients and magnesium and bicarbonate ions enter plasma along a magnesium cation concentration gradient. Magnesium functions as a bicarbonate transporter. In addition, it is suggested that bicarbonate anions enter plasma by chloride-bicarbonate exchange processes along a chloride anion concentration gradient (chloride `out`, bicarbonate `in`).

In mammals, any large increases in plasma bicarbonate concentrations can be decreased normally by a number of biochemical and physiological homeostatic control processes. These processes occur in time frames that range from minutes to hours and longer. One of the main control processes that occurs as a result of increased plasma bicarbonate concentration is an alteration in bicarbonate chemistry in the kidneys. This is manifested by a decrease in proton concentration in urine and by a pH value of urine that is less acidic. In the presence of increased plasma bicarbonate, kidney tubule cells decrease their excretion of protons. Kidney control of bicarbonate concentration is not instantaneous and occurs within a time frame of several hours to several days.

Unless a mammal has physiological or clinical acidosis, it is difficult to detect small increases in plasma bicarbonate concentration. Any increases in plasma bicarbonate concentration are taken up by body cells. Indeed, plasma bicarbonate equilibrates with intracellular bicarbonate rapidly. In a normal mammal, a measurable increase in plasma bicarbonate concentration occurs only during an artificially induced alkalosis and is detectable either when the consumption of bicarbonate anions (as NaHCO3) greatly exceeds the concentration of bicarbonate in normal plasma or when bicarbonate anions (as NaHCO3) are administered intravenously.

An experiment was conducted to determine if bicarbonate anions in aqueous metal bicarbonate solutions are translocated against a bicarbonate concentration gradient into the body. Bicarbonate translocation against a concentration gradient could occur either via energy (ATP) dependent processes or via anion (chloride-bicarbonate) exchange or via co-transport with cations along cation concentration gradients. There are also complex thermodynamic processes involving intracellular and extracellular concentrations of bicarbonate anions, hydroxide anions, protons and carbon dioxide that may assist in the overall translocation of bicarbonate anions. These processes often involve the production of bicarbonate anions by carbonic anhydrase enzymes. In the experiment, entry of bicarbonate anions into the body was assessed by determinations of proton concentration in urine; that is, the pH value of urine.

Ten people had urine pH value assessed once per week for 3 months. Urine pH values were assessed once per week for a further 3 months after commencement of consumption of aqueous metal bicarbonate solution. The aqueous metal bicarbonate solution contained approximately Mg.sup.2+ 120 mg per litre, Na.sup.+ 135 mg per litre and HCO3 950 mg per litre. The major component of the solution was magnesium bicarbonate Mg(HCO3)2 720 mg per litre approximately. Results are given below:

Mean pH value of urine,(Early Morning Sample) :
Prior to consumption of aqueous metal bicarbonate solution: pH 5.9
After commencement of consumption of aqueous metal bicarbonate solution: pH 6.7

The consumption of aqueous metal bicarbonate solution decreases proton excretion by the kidneys. The pH value of urine increases.

These results demonstrate that bicarbonate anions from aqueous metal bicarbonate solution are translocated against a bicarbonate anion concentration gradient into the body. This may occur either via co-transport with cations along a cation concentration gradient or via chloride-bicarbonate exchange processes along a chloride anion concentration gradient (chloride `out`, bicarbonate `in`). In the case of aqueous metal bicarbonate solution, the only cation concentration gradient possible is that involving magnesium cation concentrations.

The consumption of aqueous metal bicarbonate solution leads to an increase in bicarbonate anion concentration in the body which is manifested by a decrease in proton concentration in urine; an increase in pH value of urine.

etc…